Search results
Showing 736 to 750 of 2581 results for methods
Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
In development Reference number: GID-TA11488 Expected publication date: 15 July 2026
In development Reference number: GID-TA11498 Expected publication date: 29 April 2026
In development Reference number: GID-TA11254 Expected publication date: 13 May 2026
This guide describes the process NICE uses to develop NICE quality standards
These are the main stages in the multiple technology appraisal process used before April 2018.
Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
Awaiting development Reference number: GID-QS10096 Expected publication date: TBC
In development Reference number: GID-TA11330 Expected publication date: TBC
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
This interim methods and process guide for the proportionate approach to technology appraisals has been incorporated into NICE health technology evaluations: the manual.
In development Reference number: GID-TA11817 Expected publication date: 09 July 2026